PD 0360324

DRUG3 trials

Sponsors

Pfizer

Conditions

Advanced CancerArthritis, RheumatoidPulmonary Sarcoidosis

Phase 1

Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

CompletedNCT00550355

PfizerArthritis, Rheumatoid

Start: 2007-08-31End: 2009-06-30Updated: 2009-07-14

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

TerminatedNCT02554812

PfizerAdvanced Cancer

Start: 2015-11-09End: 2023-03-23Updated: 2024-07-30

Phase 2

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

TerminatedNCT01732211

PfizerPulmonary Sarcoidosis

Start: 2013-03-15End: 2013-09-23Updated: 2020-01-06

Related Papers

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Journal of Immunotherapy and Precision Oncology2023-11-249 citations

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2022-10-0152 citations

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

2017-10-23590 citations

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study.

Journal of Clinical Oncology2016-05-208 citations